2015-2016 › ... › cbmtgannualreport2016_bookle.pdf1cbmtg hhe agdofidm 3lns43lnpg 1 cbmtg annual...

CBMTG ANNUAL REPORT2015-2016

1


570 West 7th Avenue, Suite 400 Vancouver, BC V5Z 1B3 T: 604-874-4944 F: 604-874-4378 E: [email protected] W: www.cbmtg.orgCBMTG HEAD OFFICE


3

TABLE OF CONTENTS

PR ESIDEN T’S MESSAGE 4

A BOU T 5

Mission 5

Vision 5

Values 5

Philosophy 5

OrganizationChart 5

Board 6

CommitteeandSIGleads 6

HeadOfficeStaff 6

MEMBER SHIP STAT IST ICS 7

ST R AT EGIC PL A N 8

ST R AT EGIC ACHIE V EMEN TS 9

PROGR A MS 10

Webinar 10

NationalRegistry 11

GVHD2015 14

Conference2016 14

ThemedMeetings2017 15

Leadership 16

AWA R DS 16

A SSOCI AT ION SPONSOR S 17

AU DI T ED F INA NCI A L STAT EMEN TS 19

4

PRESIDENT’S MESSAGEDearCBMTGMembers,

I ampleased to present the annual report of theCanadianBlood and Marrow Transplant Group for 2015/16. Over thepast year our society has continued to grow in size andscope.At384memberstheCBMTGhasthelargestandmostdiversemembershipever.WehaverenewedourfocusonourSpecialInterestGroupsandhavebroadenedouractivitiestoincludeadvocacyinthefieldofbloodandmarrowstemcelltransplantation.

InthepastyeartheCBMTGhaspositioneditselftobethevoiceofprofessionalsworkinginthefieldofbloodandmarrowstemcell transplantation. We led the response to the MelphalanshortagelastyearandworkedcloselywithrepresentativesofHealthCanadatosecureanewsupplyofthiscriticaldrug.InordertosupportthisactivitywehaverealizedthatweneedtodevelopclosertieswiththeindividualtransplantprogramsandhaveestablishedaBMTDirectors’Committee.WehopethatthiscommitteewillenableustoadvocatemoreeffectivelyforresourcesforthecareofBMTpatients.

Wehavealsodecided to engagemorewithCanadianBMTpatientsandtheirfamilies.TheinauguralPatientSymposiumheld after the Annual Meeting in Vancouver was anopportunity to hear from patients about what would havehelpedthemgoingthroughtransplant.Many indicatedhowhard it was for them to find information about living post-transplant written from the patient’s perspective. They alsoexpressedaninterestinbecomingmoreengagedinresearchand in knowledge translation. We will continue to supportthis groupby creating a Patient and Family Special InterestGroupwithintheCBMTG.InfuturewehopetoincludePatientSymposia in future meetings to build stronger relationshipswiththesenaturalallies.

ResearchremainsacentralfocusoftheCBMTG.TheNationalRegistry continues to grow and by the end of 2016 willreceivedatafrom16Canadiantransplantcenters locatedin

all regions of the country and reflecting both pediatric andadult programs. The first publication from the registry waspresentedbyDr.K.PaulsonattheBMTTandemMeetingsinHonoluluinMarch2016.WorkhasalreadystartedonournextpublicationdescribingthestateofHCTinCanadainthe21stCentury.Dr.K. Schultz has joined theBoardof theCBMTGin the position of Director-at-Large, Research, and will belookingatinfrastructureneedstofosterinterventionalstudiesinHCTinCanada.

Our educational programs remain strong and will expandfurther under the new leadership of Dr. K. Lepic, Director-at-Large, Education. We continue to see growth in theattendanceatwebinars.WewillfocusondevelopingleadersinBMTbyhostingaleadershiptrainingprograminTorontoinNovember.Ratherthanholdingalargeannualmeetingnextyearwewillhostthreethemedmeetingsin2017;themeswillincludeInnovation(Calgary),Resilience(Winnipeg)andBeforeandAfterCare(St.John’s)andmeetingsareopentoCBMTGmembersfromacrossthecountry.WewillmeetupagainatournextAnnualMeetinginOttawainthespringof2018.

CBMTG’sgoalsintheupcomingyearwillbetocontinuetobuildtheresearchinfrastructure,encouragecollaborationbetweenprograms to address clinical, regulatory and administrativechallenges, and to further develop the association specialinterestgroups.

I wish to thank the CBMTG board of directors, committeechairs, members and staff who work towards the vision ofCBMTG. I inviteallmembers tobe involvedandparticipatewiththeassociation.

Sincerely,

Andrew Daly,MDCM, FRCPC

President


5

ABOUTTheCanadianBloodandMarrowTransplantGroup(CBMTG)isamember-led,national,multidisciplinaryorganizationprovidingleadershipandpromotingexcellenceinpatientcare,research,andeducationinthefieldofbloodandmarrowtransplant.

Our MissionThe Canadian Blood and Marrow Transplant Group is thevoice of expertsworking in the field of blood andmarrowtransplant.

VisionCanadawillbethebestplaceintheworldtohaveabloodandmarrowtransplant.

ValuesExcellence, innovation, integrity, collaboration andprofessionalismincare,educationandresearchinbloodandmarrowtransplant.

PhilosophyCBMTGbelievesthateverypatienthasarightofequalaccesstothehighestqualityoflifesavingcarethatcanbeprovidedbybloodandmarrowtransplantprofessionalsinCanada.

Organization Chart

RESEARCH COMMITTEES

ReportsviatheDirector-at-Large–Research

EDUCATION COMMITTEES

ReportviatheDirector-at-Large–Education

FINANCE COMMITTEE

ReportsviatheTreasurer

FUNDRAISING COMMITTEE

ReportsviathePresident

SPECIAL INTEREST GROUPS

ReportviatheSecretary

CBMTG BOARD OF DIRECTORSPRESIDENT,PRESIDENTELECT,PASTPRESIDENT,SECRETARY,TREASURER,EXECUTIVEDIRECTOR(EX-OFFICIO),DIRECTOR-AT-LARGE–RESEARCH,DIRECTOR-AT-LARGE–EDUCATION

CBMTG HEAD OFFICE • ReportsviathePresident

NationalRegistrySteeringCommittee

ClinicalTrialsNetwork

SmallBudgetResearchGrantsCommittee

SymposiaPlanningCommittee NursingSpecialInterestGroup

LaboratorySpecialInterestGroup

PharmacySpecialInterestGroups

PediatricBMT

PatientandFamilySpecialInterestGroup

BMTDirectorsSpecialInterestGroup

WebinarPlanningCommittee

ConferencePlanningCommittee

ThemedMeetingsPlanningCommittee

6

Committee Leads• NationalRegistrySteering:Dr. Kristjan Paulson• ClinicalTrialNetwork:Dr. Kirk Schultz• SmallBudgetResearchGrants:Dr. David Szwajcer• GVHDSymposium:Dr. Silvy Lachance

• WebinarPlanning:Dr. Mohamed Elemary• FinanceCommittee:Dr. Raewyn Broady• Fundraising:Dr. Ronan Foley• Education:Dr. Kylie Lepic

SIG Leads• Laboratory:Ms. Angela Hall• Nursing:Ms. Jennifer Wiernikowski and Ms. Samantha Mayo

• Pediatrics:Dr. Donna Wall• Pharmacy:Ms. Dawn Warketin• PatientandFamily:TBD

President, Andrew Daly, MD

Secretary, Jennifer Wiernikowski, MN, NP-Adult, CON(C)

Treasurer, Raewyn Broady, MBChB, FRACP, FRCPA, FRCPC

Director-at-Large, EducationKylie Lepic, MD

Director-at-Large, ResearchKirk Schultz, MD, FCAHS

President-Elect,Donna Wall, MD

Past President, Christopher Bredeson, MD, MSc, FRCPC

Board

Head Office Staff• Ms. Ana Torres, Executive Director

• Ms. Kimberly Tan, Association Coordinator

• Ms. Jolie Ko, Association Administrator

• Mr. Paul Fogerty, Meeting Manager

• Ms. Samantha Wale, Association Coordinator (Maternity Leave)


7

MEMBERSHIP STATISTICS

Alberta 53 members 15%

British Colombia 51 members 14%

Manitoba 18 members 5%

New Brunswick 9 members 3%

Newfoundland 5 members 1%

Nova Scotia 5 members 1%

Ontario 129 members 36%

PEI 2 members 1%

Quebec 55 members 15%

Saskatchewan 22 members 6%

International 10 members 3%

15%14%

36%

15%

1%

3% 1%

1%

3% International

5%6%

GEOGR A PHIC DIST R IBU T ION

172 154 163 162 187 249 334 335 384*

HISTORY*As of July 2016

22%

10% 19%

13%

11%

7%

5%

5%

3%

2%2% 2%

MEMBER T Y PE N UMBER %

BMTDirector 26 7%DataManager 7 2%Fellow 50 13%Lab 39 10%Nurse 73 19%AssociateDirector 11 3%Other* 41 11%Pharmacist 18 5%Physician 85 22%Professor/Assistant 19 5%ResearchScientist 7 2%Unknown 8 2%

*Other:Administrator,BMTSpecialist/BMTProcessingLead,ChiefAssistant,ClinicalAssociate,ClinicalResearchCoordinator,Coordinator,DevelopmentSpecialist,Dietitian,DonorSearchCoordinator,ExecutiveDirector,GeneralDutyTechnologist,GraduateStudent,Manager,PhysicianAssistant,ProgramManager,ProvincialLeaderofHematology&BMT,Psychologist,QualityAssurance,QualityManager,ResearchAssistant,ResearchCoordinator,Resident,ScientificDirector,SeniorManager,Donation,TMandStemCellSupervisor,Trainee,TransplantCoordinator

2008 2009 2010 2011 2012 2013 2014 2015 2016

8

STRATEGIC PLAN

the CBMTG vision is: “Canada will be the best

place in the world to have a blood and marrow

transplant.”

EDUC AT ION

Providinghighqualityeducationalprogrammesthatadvancethepracticeofbloodandmarrow

transplantationinCanada.

R ESE A RCH

Establishandorganizeaneffectiveandsustainableresearchinfrastructurefortranslationalandclinical

research.

OU T R E ACH

IncreasethevisibilityandinfluenceofCBMTGamongmembers

andthepublic.

F INA NCI A L C A PACI T Y

Tosupport,education,researchandoutreachinitiativesthroughfundraising,partnershipsandthe

establishmentofacharitableorganization.


9

STRATEGIC ACHIEVEMENTS

Education• 2016AnnualConferencesawincreasedattendanceandabstractsubmissionsfromthepreviousyear

• WesawincreasedattendancetotheCBMTGWebinars.Wehaveanewwebinarcommitteewhichisnowledby Dr.MohammedElemary

• WerecruitedanewDirector-at-Large–Education,Dr.KylieLepic

• WechangedthestructureoftheCBMTGAnnualmeetingfor2017;wewillbeholdingthreethemedmeetingsinCalgary, WinnipegandSt.John’s

• OurnextNationalMeetingwillbein2018inOttawa

Research • Theregistryincludes80%captureofallogeneictransplantsandaround60%captureofallautologoustransplants inCanada

• WerecruitedanewDirector-at-Large–Research,Dr.KirkSchultz

Outreach• CBMTGtookonaleadershiproletoaddresstheMelphalanshortage.WecollaboratedwiththeCanadianAssociationof ProvincialCancerAgencieswhenthematteraroseinlate2015

• WeestablishedacommitteeforBMTDirectorstohelpadviseonissuesofoutreach

• Firsteverpatientsymposiumin2016

Financial Capacity• Wehaveanactivefundraisingcommittee

• Wesecuredourfirstdonationtothecharity

• WewillbecollaboratingwiththeorganizersofHoleighDay.Theproceedsofthisbaseballtournamentwillbenefit CBMTG’sresearchinitiatives

• Ourfinancialpositionisgood.

10

PROGRAMS

WebinarCBMTGprovidedwebinarsfreeofchargetomembersthispastyear.ThefollowingwebinarswerepresentedsinceJanuary2016:

• NursingCollaborationtoImprovetheManagementofaCardiOncologyIn-PatientPopulation,Karen Throndson, RN MN, andDarlene Grantham, RN MN

• RoleofASCTinLightChainAmyloidosisin2016, Donna Reece, BA, MD, FRCPC

• BronchiolitisObliteransSyndrome:UpdateofDiagnosisandManagement,Guang-Shing Cheng, MD

• UnrelatedDonorSelectionGuidelines:HLAandBeyond,Stephen Spellman,MBS

• MSC’sandGVHD:WhereAreWeNowandHowDidWeGetHere?,David Allan, MD, FRCPC

• RelapseofHematologicMalignanciesPostHematopoieticStemCellTransplant,WhatisNext?,Haydar Frangoul, MD, MS

Thefollowingwebinarsareplannedfortheremainderoftheyear.

• ShouldWeIncludeAntithymocyteinPreparativeRegimensforUnrelatedDonorTransplant?,Irwin Walker, MBBS, FRACP, FRCPC

• CLLintheNovelEra,John Kuruvilla, MD, FRCPC


11

National RegistryTheCBMTGhasdevelopedacomprehensiveoutcomesregistrycontainingdetailedclinicaldataonCanadiansundergoingbothautologousandallogeneichematopoieticcelltransplantsfromprogramsacrossCanada.Wehavedataforover18,000patientsdatingbackto1990.TheRegistryisbasedinWinnipegandisundertheleadershipofDr.KristjanPaulson.TheRegistryisanimportantresearchtoolforCBMTGmembers.Somepossiblebenefitsofhavingcountry-widedata:

1. TransplantactivityandpracticesacrossCanadacanfacilitatethedesignandconductofclinicaltrialsbyCBMTGmembercentres.

2. TransplantoutcomesreflectingCanadianclinicalpractice.

3. Practicepatternsandoutcomescanbeusedbyhealthservicesresearchersandprogramstoinformpolicymakersand payersaboutNationalstandardsofpractice.

ThemajorityofthedatawillbecollectedthroughourpartnershipwithCIBMTR.AspartofFACTrequirements,transplantprogramscollectTransplantEssentialData(TED)asdefinedbytheCIBMTR.Throughdatasharingagreements,TEDformssubmittedtotheCIBMTRcanbeforwardedtotheCBMTGforinclusioninourNationalRegistry.CanadianprogramscanalsosubmittheirdatadirectlytotheCBMTGRegistry.

PA RT ICIPAT ING CEN T R ES INCLUDE:

• BritishColumbia’sChildren’sHospital,VancouverBC• VancouverGeneralHospital,Vancouver,BC• AlbertaChildren’sHospital,CalgaryAB• UniversityofCalgaryTomBakerCancerCentre,CalgaryAB• CancerCareManitoba,WinnipegMB• HealthScienceNorth,SudburyON• HamiltonHealthSciences,HamiltonON• KingstonGeneralHospital,KingstonON• PrincessMargaretHospital,TorontoON• HopitalMaisonneuve-Rosemont,MontrealQC• MontrealChildren’sHospital,McGillUniversityHealthCentre,MontrealQC• CentreHospitalierUniversitaireSainte-Justine,MontrealQC• CHAEnfantJesusHospital,QuebecCityQC• QEIIHealthSciencesCentre,DalhousieHalifaxNS• SickKidsHospital,TorontoON• OttawaHospital,Ottawa,ON(inprocess)

Thispastyear,theregistryhasseenitsfirstscientificprojectonconditioningregimensinautologoustransplantforlymphoproliferativediseases.Asecondscientificproject“TransplantinCanadainthe21stcentury”iscurrentlybeingworkedon.Threenewprojectsprojectsareunderconsiderationthisupcomingyear.

12

DATA SUMM A RY

PATIENTS PERCENT

TRANSPLANT TYPE

Allogeneic 7693 16.3%

Autologous 8794 52.9%

DLI 126 0.7%

GENDER

Male 10740 57.3

Female 7939 42.3

GRAFT SOURCE

Bonemarrow 3264 18.7%

PeripheralBlood 13731 78.6%

CordBlood 477 2.7%

YEAR OF TRANSPLANT

Before2000 7339 39%

2000-2005 4260 22.7%

2006- 7205 38.3%

AGE

Median46.1years

<18 4539 24.1%

18-40 4090 21.8%

40-60 7521 40%

>60 2654 14.1%


13

T R A NSPL A N TS BY DISE ASE

DiseaseAllogeneic Transplants

Autologous Transplants

Total

AcuteMyeloidLeukemia 2417 281 2726

AcuteLymphoblasticLeukemia 1124 18 1158

OtherAcuteLeukemia 364 6 384

ChronicMyeloidLeukemia 959 14 1023

Myeloproliferative/MyelodysplasticDiseases 821 1 830

OtherAcuteLeukemia 109 6 116

Non-HodgkinLymphoma 715 2454 3173

HodgkinLymphoma 70 1039 1109

PlasmaCellDisorder/MultipleMyeloma 197 3490 3689

OtherMalignancy 26 885 912

SevereAplasticAnemia 353 0 355

RedCellDisorder 141 0 141

Immunodeficiency 167 0 167

MetabolicDisorder 68 0 68

HistiocyteDisorder 38 0 38

AutoimmuneDisease 5 19 24

Research QueriesAresearchproposalsubmittedtotheRegistrywillbereviewedbytheScientificDirectorandRegistrydatamanagertoensurethattherequestisfeasibleandthedatarequestediscontainedwithintheRegistry,andtheprojectwillnotrequireanexcessiveamountofworkabstractbythedatamanager.Asnotedintheauthorshipproposal,ifmorethan20%ofthepatientsinthedataseriesarefromonecentre,thentheproposalwillbesenttothesteeringcommitteememberforthatcentreforcomment.ForamoredetailedreportpleaseconnectwithCBMTGheadofficeatcbmtg@cbmtg.org.

DataintheRegistryspanstheyearsof1990and2014.Atpresent,thedataareincompleteanddonotrepresentalltransplantactivityduringthistimeperiod.

14

GVHD 2015

The2015GVHDsymposiumwasheldinMontrealinthefallof2015.OnceagainwepartneredwiththeCanadianBloodServicesandHemaQuebectoputonanexcitingscientificprogram.

Presentationsincluded:

SHOULD WE INCLUDE ANTITHYMOCYTE GLOBULIN IN PREPARATIVE REGIMENS FOR UNRELATED DONOR TRANSPLANTS? PresentedbyIrwin Walker, MBBS, FRACP, FRCPC

INTESTINAL BACTERIAL FLORA AND OUTCOMES AFTER ALLOGENEIC HCT PresentedbyRobert Jenq, MD

BRONCHIOLITIS OBLITERANS SYNDROME: UPDATE ON DIAGNOSIS AND MANAGEMENT PresentedbyGuang-Shing Cheng, MD

MSC’S AND GVHD: WHERE ARE WE NOW AND HOW DID WE GET HERE? PresentedbyDavid Allan, MD, FRCPC

LATE EFFECTS AFTER ALLOGENEIC SCT IN ADULTS PresentedbyGérard Socie, MD, PhD

ZERO-INTENSITY PREPARATION ALLOGENEIC TRANSPLANT USING DONOR T-RAPA CELLS PresentedbyDaniel H. Fowler, MD

INDUCTION OF IMMUNE TOLERANCE IN PATIENTS WITH CHRONIC GVHD, PresentedbyJerome Ritz,MD

Conference Summary

The 2016 conference was chaired by Dr. Raewyn Broady and Dr. Kirk Schultz. The conferencewas scheduled for April 27 to 30, 2016 at the Westin Bayshore, Vancouver BC. The committeeconsistedof:

• Raewyn Broady, MBChB, FRACP, FRCPC (Chair)

• Kirk Schultz, MD (Chair)

• Christopher Bredeson, MD, MSc

• Jean-Sebastien Delisle, MD, PhD

• Angela Hall, BSc • Juliana Roden, MN, NP(P)

• Giovanna Cameron, MLT

• Maarten Egeler, MD, PhD

• Silvy Lachance, MD, FRCPC, CSPQ

• Jan Storek, MD, PhD

• Stephen Couban, MD, FRCPC

• Ronan Foley, MD, FRCPC

• Kirstjan Paulson, MD

• Dawn Warkentin, Pharm. D.

• Andrew Daly, MD, FRCPC

• Elie Haddad, MD, PhD

• Gizelle Popradi, MD, FRCPC

• Jennifer Wiernikowski, MN, NP-Adult, CON(C)


15

Themed Meetings 2017

Wearepleasedtoannounceaseriesofmeetingsin2017!

These1.5daylongmeetingswillincludescientificsessions,keynotepresentations,multidisciplinaryanddisciplinespecificsessionandcorporatesatellitesymposia.

WeinviteallBMThealthcareprofessionalstoattendourmeetingsin2017!

M AY 2017—W INNIPEG, M A NI TOBA

LedbyDr.DavidSzwajcerandTracyRobinson,thismeetingwillincludesessionsfocusedResilienceandEmpowerment.

J UNE 2017— C A LGA RY, A LBERTA

LedbyDr.MichelleGeddes,thismeetingwillfocusonInnovationwithintheBMTfield.

SEP T EMBER 2017—ST. JOHN’S, NE W FOUNDL A ND

LedbyDr.David Jones, thismeetingwill addressmobilizationconsiderations,bothalloandauto,and long term followup,complicationsandrelapse.

2018 CBMTG Conference

The2018CBMTGconferencewillbeheldinOttawa,ONspringof2018.COMING SOON

16

LEADERSHIPThisupcomingfalltheCBMTGwillhostaleadershipsessioninconjuctionwiththeCMA’sPhysicianLeadershipInstitute.ThegoalwillbetohelpdevelopthenextsetofleadersfromtheCanadianBMTcommunity.CBMTGwillinviteaminimumofonerepresentativefromeachCanadianBMTcentre.ThesessionwillbeheldinToronto.Formoreinformation,pleaseconnectwiththeCBMTGoffice.

AWARDSThefollowingawardswerepresentedatthe2015conference:

• HansMessnerLectureshipAward Paul Martin, MD

• FredSaundersLectureshipAward Stephan Grupp, MD, PhD

• TillandMcCullochLectureshipAward Marcel van den Brink, MD, PhD

• BestOralAbstract Denis-Claude Roy,MD

• BestPosterAward Josee Laganiere, PhD

• BestPosteraward Laura Anne Habib, MD, CM

• BestPosteraward Mia Golder, PhD

• PattyBakkestadLegare Mike Halpenny, MLT

• MostDeservingAbstractAward Kevin Dawe, BSc

Thefollowingawardswerepresentedatthe2016conference:

• HansMessnerLectureshipAward James Russell, MA, MB.BChir, FRCP

• TillandMcCullochLectureshipAward Connie Eaves, PhD, FRSC

• BestOralAbstractAwardClinical:Trials/Observations Uday Deotare, MD

• BestOralAbstractAwardClinical:Laboratory/Quality Mike Halpenny, MLT

• BestOralAbstractAwardClinical:Pharmacy/Nursing/ OtherTransplantSupport Pamela Plantinga, BSc

• BestOralAbstractAwardResearch:Basic/Translational Jacob Rozmus, MD

• BestOverallOralAbstractAward Kristjan Paulson, MD, FRCPC

• BestPosterAbstractAward Mileidys Alvarez, BSc (Hons)

• BestPosterAbstractPresentationAward Natasha Kekre, MD, MPH, FRCPC

• PattyBakkestadLegareAward Mike Halpenny, MLT andMileidys Alvarez, BSc (Hons)


17

ASSOCIATION SPONSORS

Conference sponsors

Platinum Sponsor

Gold Sponsors

Exhibitors

Lab Session Sponsor

Silver Sponsors

Symposia Supporters

Conference Supporters

Conference Contributors

AmgenInc.•BiosafeAmerica,Inc.•Celgene,Inc.•Digi-TraxCorporation•FreseniusKabiCanadaLtd.•Janssen,Inc.•JazzPharmaceuticals•LundbeckCanadaInc.•MacopharmaCanadaInc.•MerckCanada•NovartisPharmaceuticalsCanada, Inc.•OtsukaCanadaPharmaceuticalInc.•PfizerCanadaInc.•SanofiGenzyme•SeattleGenetics,Inc.•StemSoftSoftwareInc.

18

GVHD Symposia Sponsors

The 2015 sponsor of the GVHD Symposium was Sanofi.

The 2016 sponsors of the GVHD Symposium is Sanofi Genzyme and Jazz Pharmaceuticals.

National Registry Sponsor

CBMTG’s Platinum Sponsor for the Registry in 2016 is Astellas.

19


19

AUDITED FINANCIAL STATEMENTS

31


31

570 West 7th Avenue, Suite 400 Vancouver, BC V5Z 1B3 T: 604-874-4944 F: 604-874-4378 E: [email protected] W: www.cbmtg.orgCBMTG HEAD OFFICE

2015-2016 › ... › cbmtgannualreport2016_bookle.pdf1cbmtg hhe agdofidm 3lns43lnpg 1 cbmtg annual...

Documents